

IN ADULTS

*due to susceptible *H. influenzae* or *S. pneumoniae*

85%
Causative organism eliminated at end of 14-day treatment (51 of 60 patients)

91%
Causative organism eliminated at 7-day follow-up (50 of 55 patients; 5 patients did not return for follow-up)



BACTRIM™ DS

BACTRIM™

ROCHE

(trimethoprim and sulfamethoxazole)

A MAJOR ANTIMICROBIAL WITH MULTI-SYSTEM USEFULNESS

The clinical usefulness of Bactrim continues to grow. Now Bactrim is useful for all of the following infections when due to susceptible strains of indicated organisms (see indications section in summary of product information):



UPPER RESPIRATORY	*LOWER RESPIRATORY*	*GENITO-URINARY*	*GASTRO-INTESTINAL*
acute otitis media in children	acute exacerbations of chronic bronchitis in adults —documented *Pneumocystis carinii* pneumonitis	recurrent urinary tract infections	shigellosis

Before prescribing, please consult complete product information, a summary of which follows:

Indications and Usage: For the treatment of urinary tract infections due to susceptible strains of the following organisms: *Escherichia coli, Klebsiella-Enterobacter, Proteus mirabilis, Proteus vulgaris, Proteus morganii.* **It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.** *Note:* The increasing frequency of resistant organisms limits the usefulness of all antibacterials, especially in these urinary tract infections.

For acute otitis media in children due to susceptible strains of *Haemophilus influenzae* **or** *Streptococcus pneumoniae* **when in physician's judgment it offers an advantage over other antimicrobials. Use clinical information presently available on effectiveness of treatment of otitis media with Bactrim when infection is due to ampicillin-resistant** *Haemophilus influenzae.* **To date, there are limited data on the safety of repeated use of Bactrim in children under two years of age. Bactrim is not indicated for prophylactic or prolonged administration in otitis media at any age.**

For acute exacerbations of chronic bronchitis in adults due to susceptible strains of *Haemophilus influenzae* **or** *Streptococcus pneumoniae* **when in physician's judgment it offers an advantage over a single antimicrobial agent.**

For enteritis due to susceptible strains of *Shigella flexneri* **and** *Shigella sonnei* **when antibacterial therapy is indicated.**

Also for the treatment of documented *Pneumocystis carinii* **pneumonitis. To date, this drug has been tested only in patients 9 months to 16 years of age who were immunosuppressed by cancer therapy.**

Contraindications: Hypersensitivity to trimethoprim or sulfonamides; pregnant, nursing mothers; infants less than two months of age.

Warnings: BACTRIM SHOULD NOT BE USED TO TREAT STREPTOCOCCAL PHARYNGITIS. Clinical studies show that patients with group A β-hemolytic streptococcal tonsillopharyngitis have higher incidence of bacteriologic failure when treated with Bactrim than do those treated with penicillin. Deaths from hypersensitivity reactions, agranulocytosis, aplastic anemia and other blood dyscrasias have been associated with sulfonamides. Experience with trimethoprim is much more limited but occasional interference with hematopoiesis has been reported as well as an increased incidence of thrombopenia with purpura in elderly patients on certain diuretics, primarily thiazides. Sore throat, fever, pallor, purpura or jaundice may be early signs of serious blood disorders. Frequent CBC's are recommended; therapy should be discontinued if a significantly reduced count of any formed blood element is noted.

Precautions: Use cautiously in patients with impaired renal or hepatic function, possible folate deficiency, severe allergy or bronchial asthma, patients with glucose-6-phosphate dehydrogenase deficiency, hemolysis frequently dose-related, may occur. During therapy, maintain adequate fluid intake and perform frequent urinalyses, with careful microscopic examination, and renal function tests, particularly where there is impaired renal function. Bactrim may prolong prothrombin time in those receiving warfarin; reassess coagulation time when administering Bactrim to these patients.

Adverse Reactions: All major reactions to sulfonamides and trimethoprim are included, even if not reported with Bactrim. *Blood dyscrasias:* Agranulocytosis, aplastic anemia, megaloblastic anemia, thrombopenia, leukopenia, hemolytic anemia, purpura, hypoprothrombinemia and methemoglobinemia. *Allergic reactions:* Erythema multiforme, Stevens-Johnson syndrome, generalized skin eruptions, epidermal necrolysis, urticaria, serum sickness, pruritus, exfoliative dermatitis, anaphylactoid reactions, periorbital edema, conjunctival and scleral injection, photosensitization, arthralgia and allergic myocarditis. *Gastrointestinal reactions:* Glossitis, stomatitis, nausea, emesis, abdominal pains, hepatitis, diarrhea and pancreatitis. *CNS reactions:* Headache, peripheral neuritis, mental depression, convulsions, ataxia, hallucinations, tinnitus, vertigo, insomnia, apathy, fatigue, muscle weakness and nervousness. *Miscellaneous reactions:* Drug fever, chills, toxic nephrosis with oliguria and anuria, periarteritis nodosa and L.E. phenomenon. Due to certain chemical similarities to some goitrogens, diuretics (acetazolamide, thiazides) and oral hypoglycemic agents, sulfonamides have caused rare instances of goiter production, diuresis and hypoglycemia in patients; cross-sensitivity with these agents may exist. In rats, long-term therapy with sulfonamides has produced thyroid malignancies.

Dosage: Not recommended for infants less than two months of age.

URINARY TRACT INFECTIONS AND SHIGELLOSIS IN ADULTS AND CHILDREN, AND ACUTE OTITIS MEDIA IN CHILDREN:

Adults: Usual adult dosage for urinary tract infections—1 DS tablet (double strength), 2 tablets (single strength) or 4 teasp. (20 ml) b.i.d. for 10-14 days. Use identical daily dosage for 5 days for shigellosis.

Children: Recommended dosage for children with urinary tract infections or acute otitis media—8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours, in two divided doses for 10 days. Use identical daily dosage for 5 days for shigellosis.

For patients with renal impairment: Use recommended dosage regimen when creatinine clearance is above 30 ml/min. If creatinine clearance is between 15 and 30 ml/min, use one-half the usual regimen. Bactrim is not recommended if creatinine clearance is below 15 ml/min.

ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS IN ADULTS:

Usual adult dosage: 1 DS tablet (double strength), 2 tablets (single strength) or 4 teasp. (20 ml) b.i.d. for 14 days.

PNEUMOCYSTIS CARINII PNEUMONITIS:

Recommended dosage: 20 mg/kg trimethoprim and 100 mg/kg sulfamethoxazole per 24 hours in equal doses every 6 hours for 14 days. See complete product information for suggested children's dosage table.

Supplied: *Double Strength (DS) tablets,* each containing 160 mg trimethoprim and 800 mg sulfamethoxazole, bottles of 100; Tel-E-Dose® packages of 100; Prescription Paks of 20 and 28. *Tablets,* each containing 80 mg trimethoprim and 400 mg sulfamethoxazole—bottles of 100 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 40. *Pediatric Suspension,* containing in each teaspoonful (5 ml) the equivalent of 40 mg trimethoprim and 200 mg sulfamethoxazole; cherry flavored—bottles of 16 oz (1 pint). *Suspension,* containing in each teaspoonful (5 ml) the equivalent of 40 mg trimethoprim and 200 mg sulfamethoxazole, fruit-licorice flavored—bottles of 16 oz (1 pint).

ROCHE LABORATORIES
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110



works well in your office...

NEOSPORIN® Ointment

(polymyxin B-bacitracin-neomycin)

Each gram contains: Aerosporin® (Polymyxin B Sulfate) 5,000 units, bacitracin zinc 400 units, neomycin sulfate 5 mg (equivalent to 3.5 mg neomycin base); special white petrolatum qs; in tubes of 1 oz and 1/2 oz and 1/32 oz (approx.) foil packets.

works just as well in their homes.

- It's effective therapy for abrasions, lacerations, open wounds, primary pyodermas, secondarily infected dermatoses.
- It provides broad-spectrum overlapping antibacterial effectiveness against common susceptible pathogens, including staph and strep.



- It helps prevent topical infections, and treats those that have already started.
- It contains three antibiotics that are rarely used systemically.
- It is convenient to recommend without a prescription.

NEOSPORIN® Ointment—for the office, for the home.

(polymyxin B-bacitracin-neomycin)

Effective • Economical • Convenient • Recommendable

ch gram contains: Aerosporin® (Polymyxin B Sulfate) 000 units, bacitracin zinc 400 units, neomycin sulfate ng (equivalent to 3.5 mg neomycin base); special white trolatum qs; in tubes of 1 oz and 1/2 oz and 1/32 oz pprox.) foil packets.

RNING: Because of the potential hazard of nephro- icity and ototoxicity due to neomycin, care should be ercised when using this product in treating extensive rns, trophic ulceration and other extensive conditions here absorption of neomycin is possible. In burns here more than 20 percent of the body surface is ected, especially if the patient has impaired renal nction or is receiving other aminoglycoside anti- otics concurrently, not more than one application a y is recommended.

When using neomycin-containing products to control secondary infection in the chronic dermatoses, it should be borne in mind that the skin is more liable to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low grade reddening with swelling, dry scaling and itching; it may be manifest simply as a failure to heal. During long-term use of neomycin-containing products, periodic examination for such signs is advisable and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for that patient thereafter.

PRECAUTIONS: As with other antibacterial preparations, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Appropriate measures should be taken if this occurs.

ADVERSE REACTIONS: Neomycin is a not uncommon cutaneous sensitizer. Articles in the current literature indicate an increase in the prevalence of persons allergic to neomycin. Ototoxicity and nephrotoxicity have been reported (see Warning section).

Complete literature available on request from Professional Services Dept. PML.

Wellcome / **Burroughs Wellcome Co.**
Research Triangle Park
North Carolina 27709

Tomorrow's Big Picture.

Today. All of the information you need to operate an efficient, profitable practice comprises the Big Picture.

Daily and monthly financial analysis; summaries by diagnosis, by transaction and by doctor are available at the touch of a finger. And personal statement messages are part of the program.

There's more. Automatic aging. Past due notices. Month-to-date and year-to-date accounts receivable data with collection rate by doctor. Your Brig Office Management System will process claim forms and statements at a rate of three hundred per hour.

Better still, *your* people can learn to operate the system in a few minutes. For less than the cost of an outside billing service. We have leasing, purchase and rental plans.

Make the necessary decision to automate your office. Call us today for a personal demonstration.

BRIG

COMPUTERS & SOFTWARE

5830 Uplander Way, Culver City, CA 90230

(213) 641-3297 TWX 910-328-6162 in CA 1 (800) 772-2666 ext. 904 in USA 1 (800) 227-2400 ext. 904

includes Alaska, Hawaii, Puerto Rico and the Virgin Islands

Brig Computers & Software is another division of the world wide services of Pax Consolidated Corporation.



SQUIBB



When you prescribe...

day

nts

nded protection in
f mild, moderate and
hyperten on

rd provides round-the-clock control of hyper-
ion by reducing elevated systolic and diastolic
lood pressure — with a single daily dose.





They can comply.

CORGARD® (nadolol tablets) ...promotes compliance with a single daily dose

The 20- to 24-hour serum half-life of Corgard offers round-the-clock reduction in blood pressure with a once-daily dosage. With no need to interrupt daily activities to take multiple doses of medication, patients are more likely to comply.

...is often effective alone, without a diuretic[1]

Control of blood pressure with a single agent also simplifies the patient's medication schedule. Only one medication once a day means less likelihood of forgotten or skipped doses.

...rarely causes impotence, loss of libido, orthostatic hypotension*

Because it is virtually free from these undesirable side effects, the patient can function normally, without undue concern.

Prescribe

CORGARD® nadolol tablets



40 mg, 80 mg, 120 mg, and 160 mg tablets

The common-sense beta-blocker for hypertension

SQUIBB

*Please see brief summary for discussion of Contraindications, Adverse Reactions, Precautions, and Warnings, including avoidance of abrupt withdrawal, on next page of this advertisement.

The only once-a-day beta-blocker for both hypertension and angina pectoris



CORGARD®
nadolol tablets
40 mg, 80 mg, 120 mg, 160 mg scored tablets

CORGARD® TABLETS
Nadolol Tablets

DESCRIPTION: Corgard (nadolol) is a synthetic nonselective beta-adrenergic receptor blocking agent.

CONTRAINDICATIONS: Bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see WARNINGS).

WARNINGS: Cardiac Failure—Sympathetic stimulation may be a vital component supporting circulatory function in congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure; therefore, at first sign or symptom of heart failure, digitalize and/or give diuretics, and closely observe response, or discontinue nadolol (gradually if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal — Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after *abrupt* discontinuation of such therapy. When discontinuing chronic use of nadolol, particularly in patients with ischemic heart disease, gradually reduce dosage over a 1- to 2-week period and carefully monitor the patient. Reinstitute nadolol promptly (at least temporarily) and take other measures appropriate for management of unstable angina if angina markedly worsens or acute coronary insufficiency develops. Warn patients not to interrupt or discontinue therapy without physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema) — PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Administer nadolol with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of $beta_2$ receptors.

Major Surgery — Because beta-blockade impairs the ability of the heart to respond to reflex stimuli and may increase risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, withdraw beta-blockers well before surgery takes place. In emergency surgery, inform the anesthesiologist that the patient is on beta-blocker therapy. Use of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levarterenol can reverse the effects of nadolol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents.

Diabetes and Hypoglycemia — Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust dose of antidiabetic drugs.

Thyrotoxicosis — Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. To avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm, carefully manage patients suspected of developing thyrotoxicosis.

PRECAUTIONS: Impaired Hepatic or Renal Function — Use nadolol with caution in presence of either of these conditions (see DOSAGE AND ADMINISTRATION section of package insert).

Information for Patients — Warn patients, especially those with evidence of coronary artery insufficiency, against interruption or discontinuation of nadolol without physician's advice. Although cardiac failure rarely occurs in properly selected patients, advise patients being treated with beta-adrenergic blocking agents to consult physician at first sign or symptom of impending failure.

Drug Interactions — Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. When treating patients with nadolol plus a catecholamine-depleting agent, carefully observe for evidence of hypotension and/or excessive bradycardia which may produce vertigo, syncope, or postural hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility — In 1 to 2 years' oral toxicologic studies in mice, rats, and dogs, nadolol did not produce significant toxic effects. In 2-year oral carcinogenic studies in rats and mice, nadolol did not produce neoplastic, preneoplastic, or nonneoplastic pathologic lesions.

Pregnancy — In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits (but not in rats or hamsters) at doses 5 to 10 times greater (on a mg/kg basis) than maximum indicated human dose; no teratogenic potential was seen in any of these species. There are no well-controlled studies in pregnant women; therefore, use nadolol in pregnant women only if potential benefit justifies potential risk to the fetus.

Nursing Mothers — It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when nadolol is administered to a nursing woman. Animal studies showed that nadolol is found in the milk of lactating rats.

Pediatric Use — Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Most adverse effects have been mild and transient and have rarely required nadolol withdrawal.

Cardiovascular — Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). **Central Nervous System** — Dizziness or fatigue reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior reported in approximately 6 of 1000 patients. **Respiratory** — Bronchospasm reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS). **Gastrointestinal** — Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence each reported in 1 to 5 of 1000 patients. **Miscellaneous** — Each of the following reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Although relationship to drug usage is not clear, sleep disturbances have been reported. The oculomucocutaneous syndrome associated with practolol has not been reported with nadolol.

Potential Adverse Effects: Although other adverse effects reported with other beta-adrenergic blocking agents have not been reported with nadolol, they should be considered potential adverse effects of nadolol. **Central Nervous System** — reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place; short-term memory loss, emotional lability with slightly clouded sensorium; decreased performance on neuropsychometrics. **Gastrointestinal** — mesenteric arterial thrombosis; ischemic colitis. **Hematologic** — agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura. **Allergic** — fever combined with aching and sore throat; laryngospasm; respiratory distress. **Miscellaneous** — reversible alopecia; Peyronie's disease; erythematous rash.

OVERDOSAGE: Nadolol can be removed from the general circulation by hemodialysis. In addition to gastric lavage, employ the following measures as appropriate. In determining duration of corrective therapy, take note of long duration of effect of nadolol.

Excessive Bradycardia — Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.

Cardiac Failure — Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.

Hypotension — Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.)

Bronchospasm — Administer a $beta_2$-stimulating agent and/or a theophylline derivative.

DOSAGE: For all patients, DOSAGE MUST BE INDIVIDUALIZED.

For **angina pectoris,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments at 3 to 7 day intervals until optimum clinical response or pronounced slowing of the heart rate; usual maintenance dose is 80 to 240 mg q.d. (most patients respond to 1 mg or less daily). If treatment is to be discontinued, reduce dosage gradually over a period of 1 to 2 weeks (see WARNINGS).

For **hypertension,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments until optimum blood pressure reduction is achieved; usual maintenance dose is 80 to 320 mg q.d. (rarely, doses up to 640 mg may be needed).

Patients with renal failure require adjustment in dosing interval — see package insert for dosage in these patients.

For full prescribing information, consult package insert.

HOW SUPPLIED: In scored tablets containing 40, 80, 120, or 160 mg nadolol per tablet in bottles of 100 and 1000 tablets and in Unimatic® single-dose packs of 100 tablets.

Reference:

1. Data on file, Squibb Institute for Medical Research.

SQUIBB

Issued: January 1981

What they didn't teach you in medical school.

They should have taught Billing along with Biology nd Biochemistry.

Because that's the area where many professional ractices are hurting. Maybe your practice has classic mptoms—delays, delinquencies, cash flow problems.

But not to worry. Bank of America has an antidote. ur Professional Practice Management Service (PPM).

PPM is a computerized billing system that com- iles, processes, stuffs and mails your statements in a raction of the time it now takes manually.

We offer three flexible input methods designed to eet the needs of your particular practice: personal- ed; hand-written Account Entry Forms; computer rminals that let you key input directly from your ffice; or our innovative Audio Response feature where ou talk to the computer using your push-button lephone as a terminal.

PPM also automatically prepares insurance forms. hich means we can relieve you of extra processing burdens brought on by new Medi-Cal requirements.

And PPM can give you daily reports listing the status of your accounts, while providing automatic bookkeeping and posting services.

Quite simply, PPM can save you time and money. We know because we've been serving the California health care industry for over 15 years. Currently, more than 1000 professionals use our Professional Practice Management Service.

And it costs less than what you might expect. After all, we're specialists in our field, as you are in yours.

So if you're suffering from acute billing problems, call us in the morning for more information.

It could be all it takes to make your practice perfect.

BANK OF AMERICA

Corporate Electronic Banking

For more information about Bank of America's Professional Practice Management, call: Mike Wisber (415) 622-7368 or Dan DeMarco (213) 683-3742. Or mail this coupon to Bank of America, Corporate Electronic Banking, #3123, P.O. Box 37000, San Francisco, California 94137.

Name_____

Medical Offices_____

Street_____

City/State/Zip_____

Bank of America NT&SA • Member FDIC

Let **MIMS**™ take care of your paperwork while you and your staff take care of your patients . . . we think everyone will feel better.

What if

You didn't have to **worry** about:

- Cash Flow Problems
- Delays, Delinquencies
- Compiling, Processing and Stuffing Patient Bills
- Outdated and Inaccurate Reports
- The Burdens of Insurance Forms Processing

Then

You would already have a Heliosystems' Medical Information Management System (**MIMS**™).

Heliosystems offers a complete in-house computerized solution tailored to your specific needs . . . An effective means of lowering costs and increasing efficiency. It frees the physicians and staff from burdensome, repetitive paperwork and routine chores . . . and you'll no longer have to worry about ***WHAT IF's*** . . .

CALL COLLECT, (408) 946-6450, FOR YOUR "COMPUTER SYSTEM CASE STUDY" AND ADDITIONAL INFORMATION

HELIO SYSTEMS

A Division of Spectrum Management, Inc.
2195 Zanker Rd. • San Jose, CA.


SPOT-RESIST
ORAL CONTRAC
IS HERE!
It's LO/OVRAL 30. And here's how
holds spotting and breakthrough
bleeding to a minimum: Hormo
balance right from the start
throughout the cycle. Horme
ance made possible with a
dose oral contraceptive beca
the supportive progestational
of norgestrel, Wyeth's exclusive
progestogen.
Regular withdrawal bleed
despite its low dose. In clinical
amenorrhea—defined as absence
bleeding in the 7 pill-free days—
reported in only 2.1% of total cy
And when defined as absence of
bleeding for 60 days or more (as it
often is), the incidence was only 0.2%.*
And comfort for most patients*
thanks to the same balance that
helps prevent spotting and break-
through bleeding. In the clinical trials,
most patients stayed free of com-
mon side effects such as nausea
(0.6% of cycles), vomiting (0.1%),
depression (0.5%) and acne (0.9%).
©198 Wyeth Laboratories. All rights reserved.


cycle
4.2% SPOTTING
—10.6%;
—6.3%;
—4.2%
2.9% BREAKTHROUGH BLEEDING
Cycle 1—8.8%;
Cycle 3—3.3%;
Total Cycles—2.9%
100%
A near-spotless record—
in clinical trials involving 22,489 cycles*
*Serious as well as minor adverse reactions have been reported following the use of all oral contraceptives. Contraindications, Warnings, Precautions, Adverse Reactions, etc., in the accompanying insert should be carefully considered.
See full prescribing information.
LO/OVRAL®
30 mcg
each tablet contains 0.3 mg norgestrel with 0.03 mg ethinyl estradiol, Wyeth
...with a near-spotless record!
See important information on following page.

IN BRIEF:

Indications and Usage—LO/OVRAL® is indicated for the prevention of pregnancy in women who elect to use oral contraceptives (OC's) as a method of contraception.

Contraindications—OC's should not be used in women with any of the following conditions: 1. Thrombophlebitis or thromboembolic disorders. 2. A past history of deep-vein thrombophlebitis or thromboembolic disorders.
3. Cerebral-vascular or coronary-artery disease.
4. Known or suspected carcinoma of the breast.
5. Known or suspected estrogen-dependent neoplasia.
6. Undiagnosed abnormal genital bleeding. 7. Known or suspected pregnancy (see Warning No. 5). 8. Benign or malignant liver tumor which developed during use of OC's or other estrogen-containing products.

Warnings

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

The use of oral contraceptives is associated with increased risk of several serious conditions, including thromboembolism, stroke, myocardial infarction, hepatic adenoma, gallbladder disease, hypertension. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.

1. *Thromboembolic Disorders and Other Vascular Problems*—An increased risk of thromboembolic and thrombotic disease associated with use of OC's is well established. Three principal studies in Great Britain and 3 in the U.S. have demonstrated increased risk of fatal and nonfatal venous thromboembolism and stroke, both hemorrhagic and thrombotic. These studies estimate that users of OC's are 4 to 11 times more likely than nonusers to develop these diseases without evident cause.

CEREBROVASCULAR DISORDERS—In a collaborative American study of cerebrovascular disorders in women with and without predisposing causes, it was estimated that the risk of hemorrhagic stroke was 2.0 times greater in users than nonusers and the risk of thrombotic stroke was 4 to 9.5 times greater in users than in nonusers.

MYOCARDIAL INFARCTION (MI)—An increased risk of MI associated with use of OC's has been reported, confirming a previously suspected association. These studies, conducted in the UK, found, as expected, that the greater the number of underlying risk factors for coronary artery disease (cigarette smoking, hypertension, hypercholesterolemia, obesity, diabetes, history of pre-eclamptic toxemia) the higher the risk of developing MI, regardless of whether the patient was an OC user or not. OC's, however, were found to be a clear additional risk factor. In terms of relative risk, it has been estimated that OC users who do not smoke (smoking is considered a major predisposing condition to MI) are about twice as likely to have a fatal MI as nonusers who do not smoke. OC users who are also smokers have about a 5-fold increased risk of fatal MI compared to users who do not smoke, but about a 10- to 12-fold increased risk compared to nonusers who do not smoke. Furthermore, amount of smoking is also an important factor. In determining importance of these relative risks, however, baseline rates for various age groups must be given serious consideration. Importance of other predisposing conditions mentioned above in determining relative and absolute risks has not as yet been quantified; quite likely the same synergistic action exists, but perhaps to a lesser extent.

RISK OF DOSE—In an analysis of data derived from several national adverse-reaction reporting systems, British investigators concluded that risk of thromboembolism, including coronary thrombosis, is directly related to dose of estrogen in OC's. Preparations containing 100 mcg or more of estrogen were associated with higher risk of thromboembolism than those containing 50-80 mcg. Their analysis did suggest, however, that quantity of estrogen may not be the sole factor involved. This finding has been confirmed in the U.S.

ESTIMATE OF EXCESS MORTALITY FROM CIRCULATORY DISEASES—A large prospective study carried out in the UK estimated the mortality rate per 100,000 women per year from diseases of the circulatory system for users and nonusers of OC's according to age, smoking habits, and duration of use. Overall excess death rate annually from circulatory diseases for OC users was estimated to be 20 per 100,000 (ages 15-34—5/100,000; ages 35-44—33/100,000; ages 45-49—140/100,000), risk being concentrated in older women, in those with long duration of use, and in cigarette smokers. It was not possible, however, to examine interrelationships of age, smoking, and duration of use, nor to compare effects of continuous vs. intermittent use. Although the study showed a 10-fold increase in death due to circulatory diseases in users for 5 or more years, all these deaths occurred in women 35 or older. Until larger numbers of women under 35 with continuous use for 5 or more years are available, it is not possible to assess magnitude of relative risk for this younger group. Available data from a variety of sources have been analyzed to estimate risk of death associated with various methods of contraception. Estimates of risk of death for each method include combined risk of contraceptive method (e.g., thromboembolic and thrombotic disease in the case of OC's) plus risk attributable to pregnancy or abortion in event of method failure. This latter risk varies with effectiveness of method. The study concluded that mortality associated with all methods of birth control is low and below that associated with childbirth, with the exception of OC's in women over 40 who smoke. Lowest mortality is associated with condom or diaphragm backed up by early abortion. Risk of thromboembolic and thrombotic disease associated with OC's increases with age after about 30 and, for MI, is further increased by hypertension, hypercholesterolemia, obesity, diabetes, or history of pre-eclamptic toxemia, and especially cigarette smoking. Physician and patient should be alert to earliest manifestations of thromboembolic and thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, cerebrovascular insufficiency, coronary occlusion, retinal thrombosis, and mesenteric thrombosis). Should any of these occur or be suspected, the drug should be discontinued immediately.

A 4- to 6-fold increased risk of postsurgery thromboembolic complications has been reported in OC users.

If feasible, OC's should be discontinued at least 4 weeks before surgery of a type associated with increased risk of thromboembolism or prolonged immobilization.

2. *Ocular Lesions*—There have been reports of neuro-ocular lesions such as optic neuritis or retinal thrombosis associated with use of OC's. Discontinue OC's if there is unexplained, sudden or gradual, partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal-vascular lesions, and institute appropriate diagnostic and therapeutic measures.

3. *Carcinoma*—Long-term continuous administration of either natural or synthetic estrogen in certain animal species increases frequency of carcinoma of the breast, cervix, vagina, and liver. Certain synthetic progestogens, none currently contained in OC's, have been noted to increase incidence of mammary nodules, benign and malignant, in dogs. In humans, 3 case-control studies have reported an increased risk of endometrial carcinoma associated with prolonged use of exogenous estrogen in postmenopausal women. One publication reported on the first 21 cases submitted by physicians to a registry of cases of adenocarcinoma of the endometrium in women under 40 on OC's. Of cases found in women without predisposing risk factors (e.g., irregular bleeding at the time OC's were first given, polycystic ovaries), nearly all occurred in women who had used a sequential OC. These are no longer marketed. No evidence has been reported suggesting increased risk of endometrial cancer in users of conventional combination or progestogen-only OC's. Several studies have found no increase in breast cancer in women taking OC's or estrogens. One study, however, while also noting no overall increased risk of breast cancer in women on OC's, found an excess risk in subgroups of OC users with documented benign breast disease. Reduced occurrence of benign breast tumors in users of OC's has been well documented. In summary, there is at present no confirmed evidence from human studies of increased risk of cancer associated with OC's. Close clinical surveillance of all women on OC's is, nevertheless, essential. In all cases of undiagnosed persistent or recurrent abnormal vaginal bleeding, appropriate diagnostic measures should be taken to rule out malignancy. Women with a strong family history of breast cancer or with breast nodules, fibrocystic disease, or abnormal mammograms should be monitored with particular care if they elect to use OC's.

4. *Hepatic Tumors*—Benign hepatic adenomas have been found to be associated with use of OC's. One study showed that OC's with high hormonal potency were associated with higher risk than lower potency OC's. Although benign, hepatic adenomas may rupture and may cause death through intra-abdominal hemorrhage. This has been reported in short-term as well as long-term users. Two studies relate risk with duration of use of OC's, the risk being much greater after 4 or more years' use. While hepatic adenoma is rare, it should be considered in women presenting abdominal pain and tenderness, abdominal mass or shock. A few cases of hepatocellular carcinoma have been reported in women on OC's. Relationship of these drugs to this type of malignancy is not known.

5. *Use in or Immediately Preceding Pregnancy, Birth Defects in Offspring, and Malignancy in Female Offspring*—Use of female sex hormones—both estrogenic and progestational agents—during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a nonsteroidal estrogen, have increased risk of developing in later life a form of vaginal or cervical cancer ordinarily extremely rare. This risk has been estimated to be of the order of 1 in 1,000 exposures or less. Although there is no evidence now that OC's further enhance risk of developing this type of malignancy, such patients should be monitored with particular care if they elect to use OC's. Furthermore, 30 to 90% of such exposed women have been found to have epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether this condition is a precursor of vaginal malignancy. Male children so exposed may develop abnormalities of the urogenital tract. Although similar data are not available with use of other estrogens, it cannot be presumed they would not induce similar changes. An increased risk of congenital anomalies, including heart defects and limb defects, has been reported with use of sex hormones, including OC's, in pregnancy. One case-control study estimated a 4.7-fold increase in risk of limb-reduction defects in infants exposed in utero to sex hormones (OC's, hormonal withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some exposures involved only a few days. Data suggest that risk of limb-reduction defects in exposed fetuses is somewhat less than 1 in 1,000 live births. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well-controlled studies that progestogens are effective. There is some evidence that triploidy and possibly other types of polyploidy are increased among abortuses from women who become pregnant soon after ceasing OC's. Embryos with these anomalies are virtually always aborted spontaneously. Whether there is an overall increase in spontaneous abortion of pregnancies conceived soon after stopping OC's is unknown. It is recommended that, for any patient who has missed 2 consecutive periods, pregnancy should be ruled out before continuing OC's. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at time of first missed period, and further use of OC's should be withheld until pregnancy has been ruled out. If pregnancy is confirmed, the patient should be apprised of the potential risks to the fetus, and advisability of continuation of the pregnancy should be discussed. It is also recommended that women who discontinue OC's with intent of becoming pregnant use an alternate form of contraception for a period of time before attempting to conceive. Many clinicians recommend 3 months, although no precise information is available on which to base this. The administration of progestogen-estrogen combinations to induce withdrawal bleeding should not be used as a test of pregnancy.

6. *Gallbladder Disease*—Studies report increased risk of surgically confirmed gallbladder disease in users of OC's and estrogens. In one study, increased risk appeared after 2 years' use and doubled after 4 or 5 years' use. In one of the other studies, increased risk was apparent between 6 and 12 months' use.

7. *Carbohydrate and Lipid Metabolic Effects*—Decrease in glucose tolerance has been observed in a significant percentage of patients on OC's. For this reason, prediabetic and diabetic patients should be carefully observed while on OC's. Increase in triglycerides and total phospholipids has been observed in patients on OC's; clinical significance of this finding remains to be defined.

8. *Elevated Blood Pressure*—Increase in blood pressure has been reported in patients on OC's. In some women, hypertension may occur within a few months of beginning OC's. In the 1st year of use, prevalence of women with hypertension is low in users and may be no higher than that of a comparable group of nonusers. Prevalence in users increases, however, with longer exposure, and in the 5th year of use is 2½ to 3 times the reported prevalence in the 1st year. Age is also strongly correlated with development of hypertension in OC users. Women who previously have had hypertension during pregnancy may be more likely to develop elevation of blood pressure on OC's. Hypertension that develops as a result of taking OC's usually returns to normal after discontinuing the drug.

9. *Headache*—Onset or exacerbation of migraine or development of headache of a new pattern which is recurrent, persistent, or severe, requires discontinuation of OC's and evaluation of the cause.

10. *Bleeding Irregularities*—Breakthrough bleeding, spotting, and amenorrhea are frequent reasons for patients discontinuing OC's. In breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be borne in mind. In undiagnosed persistent or recurrent abnormal bleeding from the vagina, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. If pathology has been excluded, time or change to another OC may solve the problem. Changing to an OC with a higher estrogen content, while potentially useful in minimizing menstrual irregularity, should be done only if necessary, since this may increase risk of thromboembolic disease. Women with past history of oligomenorrhea or secondary amenorrhea or young women without regular cycles may have a tendency to remain anovulatory or to become amenorrheic after discontinuing OC's. Women with these pre-existing problems should be advised of this possibility and encouraged to use other methods. Post-use anovulation, possibly prolonged, may also occur in women without previous irregularities.

11. *Ectopic Pregnancy*—Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.

12. *Breast-feeding*—OC's given in the postpartum period may interfere with lactation and decrease quantity and quality of breast milk. Furthermore, a small fraction of the hormones in OC's has been identified in the milk of mothers on OC's; effects, if any, on the breast-fed child have not been determined. If feasible, defer OC's until infant has been weaned.

Precautions—GENERAL—1. A complete medical and family history should be taken prior to initiation of OC's. Pretreatment and periodic physical examinations should include special reference to blood pressure, breasts, abdomen and pelvic organs, including Pap smear and relevant laboratory tests. As a general rule OC's should not be prescribed for longer than 1 year without another physical examination.

2. Under influence of estrogen-progestogen preparations, pre-existing uterine leiomyomata may increase in size.

3. Patients with history of psychic depression should be carefully observed and the drug discontinued if depression recurs to a serious degree. Patients becoming significantly depressed while on OC's should stop OC's and use an alternate method to try to determine whether the symptom is drug-related.

4. OC's may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention, such as convulsive disorders, migraine syndrome, asthma, or cardiac or renal insufficiency.

5. Patients with a past history of jaundice during pregnancy have an increased risk of recurrence while on OC's. If jaundice develops, OC's should be discontinued.

6. Steroid hormones may be poorly metabolized in patients with impaired liver function and should be administered with caution.

7. OC users may have disturbances in normal tryptophan metabolism which may result in a relative pyridoxine deficiency. Clinical significance is undetermined.

8. Serum folate levels may be depressed by OC's. Since the pregnant woman is predisposed to development of folate deficiency and incidence of folate deficiency increases with increasing gestation, it is possible that if a woman becomes pregnant shortly after stopping OC's, she may have a greater chance of developing folate deficiency and complications attributed to this deficiency.

9. The pathologist should be advised of OC therapy when relevant specimens are submitted.

10. Certain endocrine- and liver-function tests and blood components may be affected by estrogen-containing OC's: a. Increased sulfobromophthalein retention. b. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. c. Increased thyroid-binding globulin (TBG) leading to increased circulating total-thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column, or T4 by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. d. Decreased pregnanediol excretion. e. Reduced response to metyrapone test.

Information for the Patient—See Patient Package Labeling.

Drug Interactions—Reduced efficacy and increased incidence of breakthrough bleeding have been associated with concomitant use of rifampin. A similar association has been suggested with barbiturates, phenylbutazone, phenytoin sodium, ampicillin and tetracycline.

Carcinogenesis—See Warnings on carcinogenic potential of OC's.

Pregnancy—Category X. See Contraindications, Warnings.

Nursing Mothers—See Warnings.

Adverse Reactions—An increased risk of these serious adverse reactions has been associated with use of OC's (see Warnings): thrombophlebitis, pulmonary embolism, coronary thrombosis, cerebral thrombosis, cerebral hemorrhage, hypertension, gallbladder disease, benign hepatomas, congenital anomalies. There is evidence of an association between the following conditions and use of OC's although additional confirmatory studies are needed: mesenteric thrombosis, neuro-ocular lesions, e.g., retinal thrombosis and optic neuritis.

The following adverse reactions have been reported in patients on OC's and are believed to be drug-related. Nausea and/or vomiting, usually the most common adverse reactions, occur in approximately 10 percent or less of patients during the first cycle. Other reactions, as a general rule, are seen much less frequently or only occasionally. Gastrointestinal symptoms (such as abdominal cramps and bloating); breakthrough bleeding, spotting, change in menstrual flow; dysmenorrhea, amenorrhea during and after treatment, temporary infertility after discontinuance of treatment; edema; chloasma or melasma which may persist; breast changes: tenderness, enlargement, and secretion; change in weight (increase or decrease); change in cervical erosion and cervical secretion; possible diminution in lactation when given immediately postpartum; cholestatic jaundice; migraine; increase in size of uterine leiomyomata; rash (allergic); mental depression; reduced tolerance to carbohydrates; vaginal candidiasis; change in corneal curvature (steepening), intolerance to contact lenses.

The following adverse reactions have been reported in users of OC's, and the association has been neither confirmed nor refuted: premenstrual-like syndrome, cataracts, changes in libido, chorea, changes in appetite, cystitis-like syndrome, headache, nervousness, dizziness, hirsutism, loss of scalp hair, erythema multiforme, erythema nodosum, hemorrhagic eruption, vaginitis, porphyria.

Acute Overdose—Serious ill effects have not been reported following acute ingestion of large doses of OC's by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

LO/OVRAL® each tablet contains 0.3 mg norgestrel with 0.03 mg ethinyl estradiol.

Wyeth Laboratories Phila., Pa. 19101

When she can't manage, you can.

The sweats. The hot flushes. The distress and discomfort of atrophic vaginitis. The possibility of osteoporosis.* The menopause.

For many women, it's a time of confusion and frustration. Counseling can help her overcome these feelings. But counseling *can't* stop vasomotor and vaginal symptoms, or retard bone loss*...the true signs of estrogen deficiency. And that's where she needs you most.

You're an expert at estrogen replacement. You know why it should be used. When it's best avoided. How to cycle therapy. Determine dosage. Check for contraindications and possible complications. Follow-up. You know when therapy should begin, and when it deserves to end.

Most of all, you know your patient—and when she needs the effective relief you can give her with PREMARIN.

When it comes to managing the estrogen-deficiency symptoms of the menopause, you've got what it takes.

*Conjugated Estrogens Tablets have been evaluated as probably effective for postmenopausal osteoporosis.

Prescribed with care by physicians who care.

PREMARIN®

BRAND OF

CONJUGATED ESTROGENS TABLETS, U.S.P.

0.3 mg/0.625 mg/1.25 mg/2.5 mg

Please see following page for brief summary of prescribing informatic

BRIEF SUMMARY
(FOR FULL PRESCRIBING INFORMATION AND PATIENT INFORMATION, SEE PACKAGE CIRCULAR)

PREMARIN® Brand of Conjugated Estrogens Tablets, U.S.P.

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.

Three independent case control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for more than one year.[1-3] This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.[4] The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment[1] and on estrogen dose.[3] In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study suggests that cyclic administration of low doses of estrogen may carry less risk than continuous administration;[3] it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equiestrogenic doses.

2. ESTROGENS SHOULD NOT BE USED DURING PREGNANCY.

The use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, have an increased risk of developing in later life a form of vaginal or cervical cancer that is ordinarily extremely rare.[5,6] This risk has been estimated as not greater than 4 per 1000 exposures.[7] Furthermore, a high percentage of such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis,[8-12] epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes. Several reports suggest an association between intrauterine exposure to female sex hormones and congenital anomalies, including congenital heart defects and limb reduction defects.[13-16] One case control study[16] estimated a 4.7-fold increased risk of limb reduction defects in infants exposed in utero to sex hormones (oral contraceptives, hormone withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some of these exposures were very short and involved only a few days of treatment. The data suggest that the risk of limb reduction defects in exposed fetuses is somewhat less than 1 per 1000. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progestogens are effective for these uses. If PREMARIN is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.

DESCRIPTION: PREMARIN (Conjugated Estrogens Tablets, U.S.P.) for oral administration contains a mixture of estrogens, obtained exclusively from natural sources, blended to represent the average composition of material derived from pregnant mares' urine. It contains estrone, equilin, and 17α-dihydroequilin, together with smaller amounts of 17α-estradiol, equilenin, and 17α-dihydroequilenin as salts of their sulfate esters.

INDICATIONS: Based on a review of PREMARIN Tablets by the National Academy of Sciences—National Research Council and/or other information, FDA has classified the indications for use as follows:

Effective:

1. Moderate to severe *vasomotor* symptoms associated with the menopause. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.)
2. Atrophic vaginitis.
3. Kraurosis vulvae.
4. Female hypogonadism.
5. Female castration.
6. Primary ovarian failure.
7. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
8. Prostatic carcinoma—palliative therapy of advanced disease.
9. Postpartum breast engorgement—Although estrogens have been widely used for the prevention of postpartum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.[19]

PREMARIN HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).

"Probably" effective: For estrogen deficiency-induced osteoporosis, and only when used in conjunction with other important therapeutic measures such as diet, calcium, physiotherapy, and good general health-promoting measures. Final classification of this indication requires further investigation.

CONTRAINDICATIONS: Estrogens should not be used in women (or men) with any of the following conditions: 1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2. Known or suspected estrogen-dependent neoplasia. 3. Known or suspected pregnancy (See Boxed Warning). 4. Undiagnosed abnormal genital bleeding. 5. Active thrombophlebitis or thromboembolic disorders. 6. A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast or prostatic malignancy).

WARNINGS: At the present time there is no satisfactory evidence that estrogens given to postmenopausal women increase the risk of cancer of the breast,[17] although a recent study has raised this possibility.[18] There is a need for caution in prescribing estrogens for women with a strong family history of breast cancer or who have breast nodules, fibrocystic disease, or abnormal mammograms. A recent study has reported a 2- to 3-fold increase in the risk of surgically confirmed gallbladder disease in women receiving postmenopausal estrogens.[17]

Adverse effects of oral contraceptives may be expected at the larger doses of estrogen used to treat prostatic or breast cancer or postpartum breast engorgement; it has been shown that there is an increased risk of thrombosis in men receiving estrogens for prostatic cancer and women for postpartum breast engorgement.[19-22] Users of oral contraceptives have an increased risk of diseases, such as thrombophlebitis, pulmonary embolism, stroke, and myocardial infarction.[23-30] Cases of retinal thrombosis, mesenteric thrombosis, and optic neuritis have been reported in oral contraceptive users.[31,32] An increased risk of postsurgery thromboembolic complications has also been reported in users of oral contraceptives.[33,34] If feasible, estrogen should be discontinued at least 4 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. Estrogens should not be used in persons with active thrombophlebitis, thromboembolic disorders, or in persons with a history of such disorders in association with estrogen use. They should be used with caution in patients with cerebral vascular or coronary artery disease. Large doses (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown[35] to increase the risk of nonfatal myocardial infarction, pulmonary embolism and thrombophlebitis. When doses of this size are used, any of the thromboembolic and thrombotic adverse effects should be considered a clear risk.

Benign hepatic adenomas should be considered in estrogen users having abdominal pain and tenderness, abdominal mass, or hypovolemic shock. Hepatocellular carcinoma has been reported in women taking estrogen-containing oral contraceptives.[36] Increased blood pressure may occur with use of estrogens in the menopause[37] and blood pressure should be monitored with estrogen use. A worsening of glucose tolerance has been observed in patients on estrogen-containing oral contraceptives. For this reason, diabetic patients should be carefully observed. Estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases.

PRECAUTIONS: Physical examination and a complete medical and family history should be taken prior to the initiation of any estrogen therapy with special reference to blood pressure, breasts, abdomen, and pelvic organs, and should include a Papanicolau smear. As a general rule, estrogen should not be prescribed for longer than one year without another physical examination being performed. Conditions influenced by fluid retention such as asthma, epilepsy, migraine, and cardiac or renal dysfunction, require careful observation. Certain patients may develop manifestations of excessive estrogenic stimulation, such as abnormal or excessive uterine bleeding, mastodynia, etc. Oral contraceptives appear to be associated with an increased incidence of mental depression.[23a] Patients with a history of depression should be carefully observed. Preexisting uterine leiomyomata may increase in size during estrogen use. The pathologist should be advised of estrogen therapy when relevant specimens are submitted. If jaundice develops in any patient receiving estrogen, the medication should be discontinued while the cause is investigated. Estrogens should be used with care in patients with impaired liver function, renal insufficiency, metabolic bone diseases associated with hypercalcemia, or in young patients in whom bone growth is not complete.

The following changes may be expected with larger doses of estrogen:

a. Increased sulfobromophthalein retention.

b. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.

c. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered.

d. Impaired glucose tolerance.

e. Decreased pregnanediol excretion.

f. Reduced response to metyrapone test.

g. Reduced serum folate concentration.

h. Increased serum triglyceride and phospholipid concentration.

As a general principle, the administration of any drug to nursing mothers should be done only when clearly necessary since many drugs are excreted in human milk.

ADVERSE REACTIONS: The following have been reported with estrogenic therapy, including oral contraceptives: breakthrough bleeding, spotting, change in menstrual flow; dysmenorrhea; premenstrual-like syndrome, amenorrhea during and after treatment; increase in size of uterine fibromyomata; vaginal candidiasis, change in cervical erosion and its degree of cervical secretion; cystitis-like syndrome; tenderness, enlargement, secretion (of breasts); nausea, vomiting, abdominal cramps, bloating; cholestatic jaundice; chloasma or melasma which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair, hirsutism; steepening of corneal curvature; intolerance to contact lenses; headache, migraine, dizziness, mental depression; chorea; increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; changes in libido.

ACUTE OVERDOSAGE: May cause nausea, and withdrawal bleeding may occur in females.

DOSAGE AND ADMINISTRATION: 1. *Given cyclically for short term use only:* For treatment of moderate to severe *vasomotor* symptoms, atrophic vaginitis, or kraurosis vulvae associated with the menopause (0.3 to 1.25 mg or more daily).

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.

Administration should be cyclic (*e.g.*, three weeks on and one week off).

Attempts to discontinue or taper medication should be made at three to six month intervals.

2. *Given cyclically:* Female hypogonadism. Female castration. Primary ovarian failure. Osteoporosis.

Female hypogonadism—2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days' duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on the responsiveness of the endometrium.

If bleeding occurs before the end of the 10 day period, begin a 20 day estrogen-progestin cyclic regimen with PREMARIN (Conjugated Estrogens Tablets, U.S.P.), 2.5 to 7.5 mg daily, in divided doses, for 20 days. During the last five days of estrogen therapy, give an oral progestin. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding.

Female castration and primary ovarian failure—1.25 mg daily, cyclically. Adjust upward or downward according to response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control.

Osteoporosis (to retard progression)—1.25 mg daily, cyclically.

3. *Given for a few days:* Prevention of postpartum breast engorgement—3.75 mg every four hours for five doses, or 1.25 mg every four hours for five days.

4. *Given chronically:* Inoperable progressing prostatic cancer—1.25 to 2.5 mg three times daily.

Inoperable progressing breast cancer in appropriately selected men and postmenopausal women—10 mg three times daily for a period of at least three months.

Patients with an intact uterus should be monitored for signs of endometrial cancer and appropriate measures taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.

HOW SUPPLIED: PREMARIN (Conjugated Estrogens Tablets, U.S.P.) No. 865—Each *purple* tablet contains 2.5 mg in bottles of 100 and 1,000. No. 866—Each *yellow* tablet contains 1.25 mg in bottles of 100 and 1,000. Also in unit dose package of 100. No. 867—Each *red* tablet contains 0.625 mg in bottles of 100 and 1,000. Also in unit dose package of 100. No. 868—Each *green* tablet contains 0.3 mg in bottles of 100 and 1,000.

PHYSICIAN REFERENCES: 1. Ziel, H.K., *et al.*: N. Engl. J. Med. *293*:1167-1170, 1975. 2. Smith, D.C., *et al.*: N. Engl. J. Med. *293*:1164-1167, 1975. 3. Mack, T.M., *et al.*: N. Engl. J. Med. *294*:1262-1267, 1976. 4. Weiss, N.S., *et al.*: N. Engl. J. Med. *294*:1259-1262, 1976. 5. Herbst, A.L., *et al.*: N. Engl. J. Med. *284*:878-881, 1971. 6. Greenwald, P., *et al.*: N. Engl. J. Med. *285*:390-392, 1971. 7. Lanier, A., *et al.*: Mayo Clin. Proc. *48*:793-799, 1973. 8. Herbst, A., *et al.*: Obstet. Gynecol. *40*:287-298, 1972. 9. Herbst, A., *et al.*: Am. J. Obstet. Gynecol. *118*:607-611, 1974. 10. Herbst, A., *et al.*: N. Engl. J. Med. *292*:334-339, 1975. 11. Stafl, A., *et al.*: Obstet. Gynecol. *43*:118-128, 1974. 12. Sherman, A.I., *et al.*: Obstet. Gynecol. *44*:531-545, 1974. 13. Gal, I., *et al.*: Nature *216*:83, 1967. 14. Levy, E.P., *et al.*: Lancet *1*:611, 1973. 15. Nora, J., *et al.*: Lancet *1*:941-942, 1973. 16. Janerich, D.T., *et al.*: N. Engl. J. Med. *291*:697-700, 1974. 17. Boston Collaborative Drug Surveillance Program: N. Engl. J. Med. *290*:15-19, 1974. 18. Hoover, R., *et al.*: N. Engl. J. Med. *295*:401-405, 1976. 19. Daniel, D. G., *et al.*: Lancet *2*:287-289, 1967. 20. The Veterans Administration Cooperative Urological Research Group: J. Urol. *98*:516-522, 1967. 21. Bailar, J.C.: Lancet *2*:560, 1967. 22. Blackard, C., *et al.*: Cancer *26*:249-256, 1970. 23. Royal College of General Practitioners: J.R. Coll. Gen. Pract. *13*:267-279, 1967. 23a. Royal College of General Practitioners: Oral Contraceptives and Health, New York, Pitman Corp., 1974. 24. Inman, W.H.W., *et al.*: Br. Med. J. *2*:193-199, 1968. 25. Vessey, M.P., *et al.*: Br. Med. J. *2*:651-657, 1969. 26. Sartwell, P.E., *et al.*: Am. J. Epidemiol. *90*:365-380, 1969. 27. Collaborative Group for the Study of Stroke in Young Women: N. Engl. J. Med. *288*:871-878, 1973. 28. Collaborative Group for the Study of Stroke in Young Women: J.A.M.A. *231*:718-722, 1975. 29. Mann, J.I., *et al.*: Br. Med. J. *2*:245-248, 1975. 30. Mann, J.I., *et al.*: Br. Med. J. *2*:241-245, 1975. 31. Inman, W.H.W., *et al.*: Br. Med. J. *2*:203-209, 1970. 32. Stolley, P.D., *et al.*: Am. J. Epidemiol. *102*:197-208, 1975. 33. Vessey, M.P., *et al.*: Br. Med. J. *3*:123-126, 1970. 34. Greene, G.R., *et al.*: Am. J. Public Health *62*:680-685, 1972. 35. Coronary Drug Project Research Group: J.A.M.A. *214*:1303-1313, 1970. 36. Mays, E.T., *et al.*: J.A.M.A. *235*:730-732, 1976. 37. Pfeffer, R.I., *et al.*: Am. J. Epidemiol. *103*:445-456, 1976.

7457/R

Ayerst. AYERST LABORATORIES
New York, N.Y. 10017

Classified Advertisements

The rate for each insertion is **4.00 per line** (average six words per line) **with five line minimum.**

Box number charge: $2.00 each month.

Classified display rates $40.00 per inch.

Copy for classified advertisements should be received not later than **the fifth of the month preceding issue. All copy must be typed or printed.** • Classified advertisers using Box Numbers forbid the disclosure of their identity. Your inquiries in writing will be forwarded to Box Number advertisers. The right is reserved to reject or modify all classified advertising copy in conformity with the rules of the Advertising Committee.

Please Type or Print Advertising Copy

CLASSIFIED ADVERTISEMENTS ARE PAYABLE IN ADVANCE

PHYSICIANS WANTED

CALIFORNIA: Faculty member for Family Practice Residency Program located in Orange County. Prefer Residency trained, Board Certified Family Physician. Practice and/or teaching experience preferred. Responsibilities include In-patient coordination of Residency Program or Out-Patient teaching activities. Salary negotiable. Program affiliated with University of Southern California, School of Medicine. Send all inquiries and CV to: J. Blair Pace, MD, Director, Family Practice Residency Program, Santa Ana-Tustin Community Hospital, 1001 North Tustin Avenue, Santa Ana, CA 92705. Phone: (714) 835-3555.

PHYSICIANS WANTED

GROW WITH US IN SUNNY ARIZONA—The INA Healthplan needs physicians in family practice and most specialties in Tucson and Phoenix. Attractive salaries and comprehensive benefits including a professional development program, retirement plan, and group incentive bonus are provided. If team interaction and casual living appeal to you, send your CV to: Professional Relations, INA Healthplan, Inc., 6115 North 7th Street, Phoenix, AZ 85014.

SANTA BARBARA, CALIFORNIA—53 Physician Group Practice has immediate openings in: Family Practice, Nephrology, Obstetrics/Gynecology, Oncology, Orthopedic Surgery, Pulmonary Disease, Urology, to join expanding departments in multi-specialty clinic in operation since 1921. Excellent benefit package. Must have U.S. citizenship, Board certified or eligible. CV to: Administration, Santa Barbara Medical Foundation Clinic, P.O. Box 1200, Santa Barbara, CA 93102.

SAN FRANCISCO. GP, FP, or Internist to join 3 man FG group, must be interested to become partner after 1 year. Adjacent St. Luke's Hospital. For further details call or write, L. D. Duffield, MD, 3620 Army St., San Francisco, CA 94110. Tel: (415) 826-7575.

LARGE SOUTHERN CALIFORNIA Internal Medicine and Medical Subspecialty group is seeking an internist with subspecialty in rheumatology. Contact P.O. Box 22683, San Diego, CA 92122.

EMERGENCY DEPARTMENT OPENING—Permanent and Part-Time in our group. First year salary of $78,000 includes profit sharing and pension plan, educational allowance health insurance, and part time paid at $50 per hour. Malpractice paid. Full time averages less than 40 hours per week. ED sees 43,000 annually in a 300 bed acute care hospital located in Fresno, CA. Near the High Sierras and other recreational areas. Contact Larry Marks, MD, 546 W. Morris, Fresno, CA 93704, or call collect (209) 431-3645.

ORTHOPEDIC SURGERY
OB/GYN
OTOLARYNGOLOGY
GENERAL SURGERY

We have immediate need of physicians in these and other disciplines to join us at INA/Ross-Loos Healthplan, now marking a half-century of service to Southern California members.

INA/Ross-Loos health centers are located throughout the region providing comprehensive care through utilization of community hospitals.

We offer the board eligible/certified physician an opportunity to grow with us in an environment of challenge, freedom from malpractice premiums, minimized paperwork and excellent fringe benefits.

Our compensation is highly competitive. Request details by phone or letter to:

ROSS LOOS MEDICAL GROUP, INC

ALLAN S. MIRKEN, MD
Director of Medical Personnel
INA/Ross-Loos Medical Center
1711 West Temple Street
Los Angeles, CA 90026
(213) 413-1313

PHYSICIANS WANTED

INTERNIST/GI to join a 13-physician, multispecialty group in Mount Vernon, Washington. The Medical Center is located across the street from a 126-bed hospital. Stockholder status possible after one year. Guaranteed first year salary plus liberal fringe benefits. Position available June, 1981. Contact Shane Spray, Administrator, Skagit Valley Medical Center, 1400 Kincaid, Mount Vernon, WA 98273. (206) 428-252

(Continued on Page 24)

We've taken the pain out of establishing your practice.

As a physician you're familiar with ways to alleviate pain. But chances are, your extensive educational process has not prepared you to handle the problems of selecting a location and establishing a successful private practice. National Medical Enterprises' Professional Relations Department has a staff of highly trained people who can help take the anguish out of making this important decision.

If you are familiar with NME you know us as one of America's largest and fastest growing health care companies that owns, operates, and manages acute care facilities that meet or exceed JCAH standards.

NME can provide Board Eligible/Board Certified physicians with private practice opportunities from Seattle, Washington to St. Petersburg, Florida - opportunities that enable you to concentrate on medicine while we assist you through the start-up phase of your new practice.

NME can offer you some of the best equipped health care facilities in the nation along with modern offices, a diverse climates and a community ideally suited to your lifestyle.

Let us take the pain out of establishing practice for you. Write and send us your curriculum vitae. Let us know your interests and where you want to live a practice. For additional information, contact:

Raymond C. Pruitt
Director, Physician Relations
National Medical Enterprises
11620 Wilshire Blvd.
Los Angeles, California 90025
(213) 479-5526
1-800-421-7470

NME **NATIONAL MEDICAL ENTERPRISES, INC.**

"The total health care company."

Acute pain is no laughing matter.

The first prescription for the first days of acute pain

Empirin® c̄ Codeine #3

Each tablet contains: aspirin, 325 mg; plus codeine phosphate, 30 mg, (Warning — may be habit-forming). Ⓒ III

For the millions of patients who need the potency of aspirin and codeine for their acute pain.

The pain of fractures, strains, sprains, burns and wounds is at its peak during the first three to four days following trauma. The potent action of Empirin c̄ Codeine begins to work within 15 minutes of oral administration, an important advantage during this acute pain period. Empirin c̄ Codeine has unique bi-level action to attack pain at two critical points: peripherally at the site of injury and centrally at the site of pain awareness.

For the most effective dosage in treating acute pain, begin with... two tablets of Empirin c̄ Codeine #2 or #3, every four hours. Titrate downward as pain subsides.

EMPIRIN® with Codeine

DESCRIPTION: Each tablet contains aspirin (acetylsalicylic acid) 325 mg plus codeine phosphate in one of the following strengths: No. 2 — 15 mg, No. 3 — 30 mg, and No. 4 — 60 mg. (Warning — may be habit-forming.) Ⓒ III

CONTRAINDICATIONS: Hypersensitivity to aspirin or codeine.

WARNINGS:

Drug dependence: Empirin with Codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of this drug and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral, narcotic-containing medications. Like other narcotic-containing medications, the drug is subject to the Federal Controlled Substances Act.

Use in ambulatory patients: Empirin with Codeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.

Interaction with other central nervous system (CNS) depressants: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) concomitantly with Empirin with Codeine may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Use in pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development. Therefore, Empirin with Codeine should not be used in pregnant women unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.

PRECAUTIONS:

Head injury and increased intracranial pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute abdominal conditions: The administration of Empirin with Codeine or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Allergic: Precautions should be taken in administering salicylates to persons with known allergies: patients with nasal polyps are more likely to be hypersensitive to aspirin.

Special risk patients: Empirin with Codeine should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture, peptic ulcer, or coagulation disorders.

ADVERSE REACTIONS: The most frequently observed adverse reactions to codeine include light-headedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation, and pruritus.

The most frequently observed reactions to aspirin include headache, vertigo, ringing in the ears, mental confusion, drowsiness, sweating, thirst, nausea, and vomiting. Occasional patients experience gastric irritation and bleeding with aspirin. Some patients are unable to take salicylates without developing nausea and vomiting. Hypersensitivity may be manifested by skin rash or even an anaphylactic reaction. With these exceptions, most of the side effects occur after repeated administration of large doses.

DOSAGE AND ADMINISTRATION: Dosage should be adjusted according to the severity of the pain and the response of the patient. It may occasionally be necessary to exceed the usual dosage recommended below in cases of more severe pain or in those patients who have become tolerant to the analgesic effect of narcotics. Empirin with Codeine is given orally. The usual dose for Empirin with Codeine No. 2 and No. 3 is one or two tablets every four hours as required. The usual adult dose for Empirin with Codeine No. 4 is one tablet every four hours as required.

DRUG INTERACTIONS: The CNS depressant effects of Empirin with Codeine may be additive with those of other CNS depressants. See WARNINGS.

Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

(Continued from Page 22)

PHYSICIANS WANTED

WYOMING: Emergency Medicine—Summer locum tenens for experienced emergency physicians in busy resort hospital located in Jackson, Wyoming. Average of 56 hours per week with flexible scheduling arrangement. Must be available June 5 through September 14 inclusive, without exception. Excellent hourly compensation plus paid professional liability insurance. For further information, contact William Salmo at 1-(800)-525-3681 (in Colorado call collect (303) 471-4981).

ORTHOPEDIC SURGEON—Board Certified, Orthopedic Surgeon needed at VA Medical Center, Livermore, CA. Ideal living, good climate and clean air. Malpractice insurance not needed. Position available at present. Salary dependent upon experience and qualifications. Contact: John F. Kane, MD, Chief of Staff, VA Medical Center, Livermore, CA 94550. Tel: (415) 447-2560, ext. 204.

WANTED: Univ. trained general surgeon needed to join two other general surgeons in 13 man clinic. Excellent qualifications required. Location: southern Idaho, near excellent outdoor recreation. Write Box 1233, Twin Falls, ID 83301.

SAN FRANCISCO BAY AREA—45-MD multispecialty private group practice established 25 years ago, seeking an orthopedic surgeon for medical/industrial office work to assist our busy 2 physician department in their general orthopedic work. Excellent location in the Santa Clara Valley, 45 minutes from San Francisco, 10 minutes from Stanford University. Send CV to: Walter Saphir, MD, Sunnyvale Medical Clinic, 596 Carroll St., Sunnyvale, CA 94086.

EMERGENCY MEDICINE OPPORTUNITIES, full and part-time, in the Rocky Mountain states for career oriented emergency physicians. Excellent compensation and paid professional liability insurance. Send credentials to Mr. William Salmo, Chase Stone Center, Holly Sugar Building, Suite 440, Colorado Springs, CO 80903. Or call toll-free 1 (800) 525-3681 (in Colorado call collect (303) 471-4981).

CALIFORNIA, San Jose: Primary Care Physician with experience in Peds. and minor trauma wanted to staff ambulatory care clinic at large teaching hospital in San Francisco Bay Area. Flexible hours, independent contractor status with hourly compensation. For further details, please call or write: Eve Campbell, 1550 The Alameda, No. 314, San Jose, CA 95126. Tele: (408) 293-8881.

ASSISTANT DIRECTOR
Human Services Agency
Mental Health Services

The Orange County Human Services Agency is seeking a highly qualified Mental Health professional to serve as Assistant Agency Director. Responsible for centralized mental health functions and for quality control of mental health services provided within the agency's multi-discipline regional structures. Experienced Psychiatrists, clinical social workers, clinical Psychologists or hospital/health care administrators with strong mental health and administrative background may qualify. Annual salary of $46,200 to $69,720 based on merit. The starting salary is negotiable. Final filing date March 31, 1981.

To apply, contact
HSA, PERSONNEL
515 N. SYCAMORE
SANTA ANA, CALIFORNIA
or call (714) 834-7828

Affirmative Action Employer M/F

PHYSICIANS WANTED

GENERAL SURGEON—needed in established multispecialty clinic in beautiful university town. First year guaranteed with full fringe benefits and incentive, new hospital, four season recreation, and ideal family environment. Contact The Budge Clinic, 225 E. 4th North, Logan, UT 84321.

GENERAL/FAMILY PRACTICE PHYSICIANS (2) needed by 31 member multi-specialty group. Excellent practice opportunity; benefits and retirement program; all practice costs paid; early shareholder status. Reply D. R. Molesworth, Administrator, San Luis Medical Clinic, Ltd., 1235 Osos Street, San Luis Obispo, CA 93401.

CALIFORNIA—B.E./B.C. Family Physician, Emergency Physician or Internist wanted for new multi-Specialty group in desirable Roseville suburb of Sacramento. Combines office practice with part-time Minor Emergency Clinic practice. Competitive salary. Fringe; leads to partnership. Excellent hospital and office facilities. One position avail. immed., one avail. in Spring, 1981. Contact: Joseph Rosenfield, Adm., Western Medical Group, 6330 Main Ave., Orangevale, CA 95662, (916) 988-9544.

INFECTIOUS DISEASE Specialist wanted to join another busy ID Specialist in private practice in growing city in Northwest. Please send CV to Box 6163, Western Journal of Medicine, 731 Market St., San Francisco, CA 94103.

RADIOLOGIST: Board certified, experienced all major modalities plus board eligible and/or certified in nuclear medicine or equivalent, join group in hospital practice Southern California. Full curriculum vitae initial reply, Box 6177, Western Journal of Medicine, 731 Market St., San Francisco, CA 94103.

OPHTHALMOLOGIST needed to fill recent vacancy in busy practice designed for 2 physicians. Join Board Certified Ophthalmologist in practice in this friendly Ohio city. General ophthalmology or retina practice. $75,000 plus fringes first year. Full partnership buy in possible after first year. Respond with CV to Box 6183, Western Journal of Medicine, 731 Market St., San Francisco, CA 94103.

GENERAL PRACTITIONER/F.P.—private practice opportunity in association with acute-care general hospital in Santa Maria, CA. Fully accredited CMA and JCAH with 24-hour E.R. Excellent guarantee of annual gross billings, free office rent, other financial assistance available. Located within 10 miles of beaches and lakes. Interested physicians please send C.V. to Marsha Mayer, Director of Physician Recruiting, SUMMIT HEALTH LTD., 4070 Laurel Canyon Blvd., Studio City, CA 91604, or call collect (213) 985-8386.

POSITIONS AVAILABLE IN GENERAL MEDICINE: Board certified or Board eligible preferred. Beginning salary from $38,000 to $50,000 per year depending upon qualifications, plus automatic pay bonus of $15,000 to $24,500 per year. Complete malpractice insurance coverage provided. Liberal fringe benefits—life insurance, health insurance, retirement, 30 days vacation plus 15 days sick leave each year. An unexcelled opportunity to engage in a challenging medical practice in a rural setting offering unlimited recreational opportunities—hunting, fishing, skiing, plus fresh, clear air in abundance. Contact: Norman C. Jorgenson, MD, Chief of Staff, Veterans Administration Medical Center, Miles City, MT 59301. Telephone (406) 232-3060, or FTS 585-9201. An Equal Opportunity Employer.

CARDIOLOGIST, PULMONOLOGIST, UROLOGIST, DERMATOLOGIST, & ORTHOPEDIC HAND SURGEON: Immediate openings for fully trained, Board Certified or eligible physicians in a multi-specialty group. Complete pulmonary laboratory facilities. Attractive San Francisco Bay Area. Send CV to Recruitment Committee, San Jose Medical Clinic, 45 South 17th Street, San Jose, CA 95112.

Excellent opportunities exist in prime geographical locations throughout the Western, Midwestern and Rocky Mountain states for General and Family Practice Physicians. Access to hunting, fishing, skiing, boating and other excellent recreational activities. Top school systems and warm community atmosphere. Unlimited opportunity to make an impact. Compensation package includes base guarantee, incentives and fringe benefits. Complete medical practice support. The future holds unlimited growth potential. For information contact:

Advanced Health Systems, Inc.
Professional Placement
17861 Cartwright Road
Irvine, CA 92714
or call toll-free (800) 854-3020
EOE M/F

PHYSICIANS WANTED

COLORADO EMERGENCY MEDICINE: Directorship and Clinical positions available in Northeastern portion of the state in moderate volume emergency department. Hourly guarantee plus compensation for Director's added responsibilities. Paid professional liability insurance and other amenities. For further information contact William Salmo toll-free 1 (800) 525-3681 (within Colorado call collect (303) 471-4981); or send credentials in confidence to Chase Stone Center, Holly Sugar Building, Suite 1070, Colorado Springs, CO 80903.

LAS VEGAS, NEVADA: Emergency Medicine Opportunity-Clinical position available in the modern facility south of Las Vegas. Flexible scheduling according to individual needs allows time to enjoy the numerous recreational facilities in the surrounding countryside. Minimum guarantee plus paid professional liability insurance. For details send credentials in confidence to William Salmo, Chase Stone Center, Holly Sugar Building, Suite 1070, Colorado Springs, CO 80903 or call toll-free 1 (800) 525-3681 (within Colorado, call collect (303) 471-4981).

(Continued on Page 34)

DEVELOPMENTAL DISABILITIES PROGRAMS

Opportunities are available for internists, family practitioners and psychiatrists to work with developmentally disabled people in State residential communities. Locations from Los Angeles to northern California. Challenging and varied cases, congenial professional environment, excellent civil service benefits.

Hospital Recruitment Program
Dept. of Developmental Services
714 P Street
Sacramento, CA 95814
(916) 322-1221 collect

The Sequoia Medical System Avoids Complications





The Sequoia Medical System. A sophisticated, efficient office organizer and medical assistant. Designed to be easy to use.

Now you can put the computer's organizational and information-handling power to good use in your practice. The Sequoia Medical System, designed and developed precisely for the small group or solo practice physician, provides complete office support, including financial analysis, third party billing, and patient data management. But most importantly, Sequoia is easy to use.

Ordinary English

No computer knowledge is needed to talk to the Sequoia system. Everything is done in English so plain that you'll forget you're talking to a computer. Sequoia gives you simple instructions, clear task descriptions, and frequent directions along the way. Details on taking the system through its paces are listed menu style—and displayed in soft, green letters on a swivel screen designed to prevent glare and eye-strain. The keyboard on your terminal will probably look familiar: it's the IBM Selectric now being used in most offices.

Training and support

Prior to installing your medical system, Sequoia provides your staff with comprehensive training at a Sequoia Training Center. After training is completed, you and your staff can use the Sequoia Hot Line to answer any questions that might arise. This Hot Line support even allows us to communicate with your system by telephone from the Sequoia home office.

For further assistance, we also have Customer Support Representatives in local offices throughout the U.S. They're available to visit your office and work with you and your staff on an ongoing basis.

Comprehensive training and continuous support help to make the Sequoia System easy to use.

System growth

As your practice grows, each Sequoia System can be expanded with additional terminals, patient data storage, and programs. Plus, Sequoia continually updates programs to keep your system in step with the latest technology. So you can choose to start with the simplest, least expensive system, and add capabilities as your needs grow. With Sequoia, system growth is flexible and easy.

Specialization

Sequoia was designed specifically for medical practice management. It blends into your office routine with the efficiency of a professional—quickly and easily.

To find out more about Sequoia, write for a free informational brochure to the Sequoia Group, 1100 Larkspur Landing Circle, Larkspur, California 94939. Or dial the toll-free number below and discuss your needs with us. Like our medical system, we're easy to talk to.

Call toll-free **(800) 227-2360**; in California, call **(800) 772-2655.**

SEQUOIA GROUP™

INCORPORATED

Atlanta, Birmingham, Boston, Buffalo, Charlotte, Chicago, Columbus, Dallas, Denver, Detroit, Hartford, Houston, Indianapolis, Irvine, Kansas City, Los Angeles, Memphis, Miami, Minneapolis, Nashville New Orleans, New York City, Norfolk, Oklahoma City, Philadelphia, Phoenix, Pittsburgh, Portland, Salt Lake City, San Antonio, San Diego, San Francisco, Seattle, St. Louis, Tampa, Washington, D.C.

Visit us in Booths 61 through 66 at the CMA Convention

Yesterday's Folk Remedy:

A rye loaf in the rafters.



Early in this century in Central Europe, almost every farm family kept a loaf of moldy rye bread on one of the kitchen beams. When any family member was cut or bruised, it was an old custom to cut a thin slice from the outside of the loaf, mix it into a paste with water, and apply it to the wound with a bandage. It was believed that no infection would then result from the cut.[1]



Today's Tradition:

Tegopen®

(cloxacillin sodium)

for the treatment* of known or suspected staphylococcal infections such as:

- Acute sinusitis
- Furunculosis and carbuncles
- Impetigo
- Secondarily infected dermatitis
- Cellulitis
- Abscesses
- Infected sebaceous cysts

In serious, deep-seated staph infections, 500 mg q.i.d. dosage is recommended.†

- Tegopen has been reported active against 96% of *Staphylococcus aureus*.[2]
- 80% of *S aureus* has been reported resistant to amoxicillin and ampicillin.‡[2]
- 88% of *S aureus* has been reported resistant to penicillins G and V.‡[2]
- Staph resistance to erythromycin may develop during a course of therapy.[3]

Available as 500-mg and 250-mg capsules and Oral Solution 125 mg/5 ml.

Tegopen® (cloxacillin sodium)
Today's Penicillin for Today's Physician

1. Florey HW, Chain E, Heatley NG, et al: *Antibiotics.* London, Oxford University Press, 1949, p 2.
2. Bac-Data Bacteriologic Report, Professional Market Research, 1978-1979. The clinical significance of *in vitro* data is unknown.
3. Erythromycin prescribing information (in *Physicians' Desk Reference,* ed 34. Oradell, NJ, Medical Economics Co, 1980) states that staph resistance may develop during treatment.

See brief summary of prescribing information on an adjoining page.

*Note: The choice of Tegopen should take into consideration the fact that it has been shown to be effective only in the treatment of infections caused by pneumococci, Group A beta-hemolytic streptococci, and penicillin G-resistant and penicillin G-sensitive staphylococci. If the bacteriology report later indicates that the infection is due to an organism other than a penicillin G-resistant staphylococcus sensitive to cloxacillin sodium, the physician is advised to continue therapy with a drug other than cloxacillin sodium or any other penicillinase-resistant semisynthetic penicillin.

†In serious, life-threatening infections, oral preparations of the penicillinase-resistant penicillins should not be relied on for initial therapy.

‡Not all isolates may have been tested using both discs.

ULD YOU GUARANTEE THERE WON'T BE PROBLEMS ER THE NEXT 5 YEARS?

THER WOULD WE.



esponsible physicians know at despite sound medical judgent and specialized skills, their ognoses are often subject to ncertainty.

You must make allowances for otential adversity and you should xpect your professional liability surance company to do the same.

Responsible medical malpractice surers, like The Doctors' Company, now that their policyholders' longnge interests are best protected y financial strength and solvency.

That's why we maintain the largest surplus of all the doctor-owned malpractice insurers in the western United States. That's why our earned premium to surplus ratio is the most favorable of all these companies. And that's why we continue to collect surplus contributions from new members.

Future results can't be guaranteed, in the fragile art of medicine or in the volatile business of malpractice insurance. Our allowance for adversity is surplus.

For details about our program, call or write: The Doctors' Company, 233 Wilshire Blvd., Santa Monica, CA 90401. (213) 451-9936. Toll free, (800) 352-7271. Outside California, (800) 421-2368.

THE DOCTORS' COMPANY

AN INTERINSURANCE EXCHANGE
OFFERING MEDICAL MALPRACTICE INSURANCE
TO DOCTORS IN
CALIFORNIA, NEVADA, WYOMING AND MONTANA

In Hypertension*...When You Need to Conserve K^+

Every Step of the Way



Each capsule contains 50 mg. of Dyrenium® (brand of triamterene) and 25 mg. of hydrochlorothiazide.

EFFECTIVE STEP 1 DIURETIC THERAPY† *(when the combination represents previously titrated dosage)*

†Step 1 usually consists of an initial phase (a diuretic alone), a titration phase (dosage adjustment and/or addition of a K^+ supplement or K^+-sparing agent and a maintenance phase (a diuretic alone or in combination with a K^+ supplement or K^+-sparing agent).

Serum K^+ and BUN should be checked periodically (see Warnings).

Before prescribing, see complete prescribing information in SK&F Co. literature or *PDR*. A brief summary follows:

* **WARNING**
This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. **Associated widened QRS complex or arrhythmia, requires prompt additional therapy.** Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Watch for signs of impending coma in severe liver disease. If spironolactone is used concomitantly, determine serum K^+ frequently; both can cause K^+ retention and elevated serum K^+. Two deaths have been reported with such concomitant therapy (in one, recommended dosage was exceeded, in the other serum electrolytes were not properly monitored). Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic anemia have been reported with thiazides. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effect may be enhanced in postsympathectomy patients. Use cautiously in surgical patients. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia, although uncommon, has been reported. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances. Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and, rarely, allergic pneumonitis have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components.

Supplied: Bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

SK&F CO
a SmithKline compa
Carolina, P.R. 00630

medi+physics

Announces An Ideal Radioisotope For The Study of Pulmonary Ventilation

- A half-life of 13 seconds and decay by Isomeric Transition means low radiation exposure to patients and staff.
- The monoenergetic gamma emission of 191 keV is well suited for the gamma camera.
- No special radioactive gas collection or disposal system required.
- Completely portable system allows studies in ICU, CCU, and Post-Surgical departments with portable camera.

Krypton Kr 81m Gas Generator

- Studies can be conducted on comatose, uncooperative, or mechanically vented patients.
- Distribution of radioactive gas is mainly to the lungs.
- Elaborate delivery system is not required.
- The only radioisotope that can be administered ON and OFF as needed.
- Easy to license when compared to Xenon Xe 133 gas.

ata from 231 hospitals, compiled by an independent bacteriologic monitoring service, show:

More isolates of more common uropathogens sensitive to Bactrim than to any other frequently prescribed antimicrobial

r cent of isolates of common uropathogens sensitive to Bactrim and to other antimicrobials



Numbers in parentheses indicate projected number of isolates tested with antibacterial.
Source: BacData Medical Information Systems, Inc., Summer 1980.
*Tested with cephalothin disc, recommended as representative of all cephalosporins.

Bactrim consistently proves its *in vitro* effectiveness against the organisms estimated to cause 90-95% of urinary tract infections: *E. coli, Proteus mirabilis, Klebsiella* and *Enterobacter* species.[4,5] Susceptibility tests are believed to correlate more closely with clinical results in urinary tract infections than in any other kind.[4]

No significant change seen in resistance patterns

Uropathogens sensitive to Bactrim have demonstrated no significant increased resistance *in vitro* after many years of use in patients with urinary tract infection.[6] In one study,[7] SMX/TMP (Bactrim), given over a period of four weeks, was not followed by emergence of resistant strains of Enterobacteriaceae—a result noted to correlate with clinical findings that in patients given SMX/TMP, urinary tract reinfections with resistant organisms are rare.

It is important to maintain adequate fluid intake during therapy. Bactrim is contraindicated during pregnancy at term, the nursing period, in patients hypersensitive to its components, and in infants under 2 months of age.

References: **1.** Rubin RH, Swartz MN: *N Engl J Med 303*: 426-432, Aug 21, 1980. **2.** Dhalla S, Flynn JT: *NY State J Med 80*: 1087-1094, June 1980. **3.** Stamey TA: *J Urol 109*: 467-472, Mar 1973. **4.** Kunin CM: *Detection, Prevention and Management of Urinary Tract Infections*, ed 3. Philadelphia, Lea & Febiger, 1979, pp. 91, 140. **5.** Mayer TR: *Geriatrics 35*: 67-77, Mar 1980. **6.** BacData Medical Information Systems, Inc., Winter 1976-1977 to Summer 1980. **7.** Knothe H: *Infection 7* (Suppl 4): S321-S323, 1979.

Bactrim™ DS

160 mg trimethoprim and 800 mg sulfamethoxazole

maximizes results with B.I.D. convenience

ROCHE®

Please see summary of product information on following page.

Bactrim

in recurrent urinary tract infection

attacks pathogens from site to sourc

Bactrim continues to demonstrate high clinical effectiveness in recur urinary tract infections. Bactrim reaches effective levels in urine, seru and renal tissue[1]...the trimethoprim component diffuses into vaginal secretions in bactericidal concentrations[1]...and in the fecal flora, Bactrim effectively suppresses Enterobacteriaceae[1,2] with little result emergence of resistant organisms.

succeeds

in acute exacerbations of chronic bronchitis†

powers the volume, clears the sputum

...e to susceptible strains of ...amophilus influenzae or Strep... ...occus pneumoniae when in the ...gment of the physician Bactrim ...rs some advantage over the ...of a single antimicrobial ...int.

...lubin RH, Swartz MH. *N Engl J ...* 303:426-432, Aug 21, 1980 ...Data on file, Medical Depart... ...ent, Hoffmann-La Roche Inc.

In controlled multicenter studies involving *H. influenzae* and *S. pneumoniae*, a 7-day follow-up after 14-day treatment showed the causative organisms were eliminated in 50 of 55 patients (91%).[2] Five patients did not return for follow-up.

During therapy, maintain adequate fluid intake. Bactrim is contraindicated during pregnancy at term and lactation, in patients hypersensitive to its components, and in infants less than two months of age.

...ith B.I.D. convenience...

Bactrim™ DS

(800 mg sulfamethoxazole and 160 mg trimethoprim)

ROCHE

...see next page for summary of product information

Only one beta-blocker provides once-a-day round-the-clock protection in both angina pectoris and hypertension.

CORGARD
[nadolol tablets]
IS THE ONE



Reliable 24-hour beta blockade at all titrated dosages

SQUIBB

Innovators in cardiovascular medicine

See brief summary

THEO-DUR®
(anhydrous theophylline)

BECAUSE YOU DON'T HAVE TO TOLERATE ASTHMA ATTACKS.

Unlike beta agonists, Theo-Dur is indicated for asthma prophylaxis.[1]

Many bronchodilators can treat an acute attack of asthma. But not many can prevent an attack from starting.

Theo-Dur is unique. It is the only form of oral theophylline to demonstrate linear, therapeutic blood levels for a full 12 hours. This minimizes the problems of toxicity or therapeutic failure common to other oral theophyllines.

On a q12h dose of Theo-Dur patients can enjoy a full day of normal activities and a night of uninterrupted sleep. In addition, prophylactic Theo-Dur therapy offers an increase in exercise tolerance, the likelihood of fewer emergency visits and a greater reduced need for concomitant therapy.

AND YOU WON'T HAVE TO WORRY ABOUT TOLERANCE.

Unlike beta agonists, no development of tolerance appears to occur with chronic use of theophylline."[1]

Beta agonists act by stimulating $beta_2$ receptors in bronchial smooth muscle. This stimulus results in increased levels of cyclic AMP, which triggers the series of biochemical events leading to bronchodilation.

Beta agonists may be difficult to control in chronic use.

There is concern that chronic use of beta agonists can lead to clinically important drug tolerance.[2] Repeated stimulation of receptors by beta agonists causes an eventual reduction in the number of receptor sites and a decreased ability to produce cyclic AMP. The result: a potential decline in both magnitude and duration of bronchodilator response.[3]

This may help account for the fact that more than half of all patients on beta agonists require concomitant therapy, usually a theophylline.[4]

Theophylline: no evidence of tolerance.

Unlike beta agonists, theophylline appears to act through the inhibition of phosphodiesterase, the enzyme which breaks down cyclic AMP. Theophylline has no effect on the number of $beta_2$ receptors and therefore has none of the potential for tolerance seen with beta agonists.

Conclusion: Current thinking strongly suggests that beta agonists should be reserved for use in acute attacks. Theo-Dur is indicated for both relief and prophylaxis of bronchospasm.

Today's most widely prescribed bronchodilator.

THEO-DUR®

(anhydrous theophylline)

Sustained Action Tablets

KEY PHARMACEUTICALS, INC.

Please see next page for a summary of prescribing information.

Motrin® vs aspirin w/codeine...
(ibuprofen)

compare the analgesic effect

A *Motrin* 400 mg dose relieved postsurgical dental pain as effectively as a combination of 650 mg aspirin and 60 mg codeine (two aspirin-with-codeine No. 3 tablets) in a study of 129 patients. In this double-blind, placebo-controlled, randomized study, no statistically significant difference in relief of pain was noted at 1, 2, and 4 hours between the *Motrin* and aspirin-with-codeine groups... with *Motrin* being significantly more effective ($p = 0.03$) at the three-hour interval. Active treatment was significantly more effective ($p < 0.0001$) than placebo at all time intervals.

Comparison of pain relief
Motrin vs aspirin-codeine combination



Data on file at The Upjohn Company.

One tablet q4-6h prn
For relief of mild to moderate pain:

Motrin® 400 mg TABLETS
ibuprofen, Upjohn

• Not a narcotic • Not addictive • Not habit forming • Nonscheduled • Acts peripherally • Relieves pain rapidly • Relieves inflammation • Indicated in acute and chronic pain • Well tolerated (The most common side effect with *Motrin* is mild gastrointestinal disturbance.)

Please turn the page for a brief summary of prescribing information.

Upjohn



Only Valium® (diazepam/Roche) is indicated in anxiety disorders and as an adjunct in the relief of skeletal muscle spasm

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Management of anxiety disorders, or short-term relief of symptoms of anxiety; symptomatic relief of acute agitation, tremor, delirium tremens and hallucinosis due to acute alcohol withdrawal; adjunctiveiy in skeletal muscle spasm due to reflex spasm to local pathology; spasticity caused by upper motor neuron disorders; athetosis; stiff-man syndrome; convulsive disorders (not for sole therapy).

The effectiveness of Valium (diazepam/Roche) in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Contraindicated: Known hypersensitivity to the drug. Children under 6 months of age. Acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving appropriate therapy.

Warnings: Not of value in psychotic patients. Caution against hazardous occupations requiring complete mental alertness. When used adjunctively in convulsive disorders, possibility of increase in frequency and/or severity of grand mal seizures may require increased dosage of standard anticonvulsant medication; abrupt withdrawal may be associated with temporary increase in frequency and/or severity of seizures. Advise against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms similar to those with barbiturates and alcohol have been observed with abrupt discontinuation, usually limited to extended use and excessive doses. Infrequently, milder withdrawal symptoms have been reported following abrupt discontinuation of benzodiazepines after continuous use, generally at higher therapeutic levels, for at least several months. After extended therapy, gradually taper dosage. Keep addiction-prone individuals under careful surveillance because of their predisposition to habituation and dependence.

Usage in Pregnancy: **Use of minor tranquilizers during first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.**

Precautions: If combined with other psychotropics or anticonvulsants, consider carefully pharmacology of agents employed; drugs such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants may potentiate its action. Usual precautions indicated in patients severely depressed, or with latent depression, or with suicidal tendencies. Observe usual precautions in impaired renal or hepatic function. Limit dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation.

Side Effects: Drowsiness, confusion, diplopia, hypotension, changes in libido, nausea, fatigue, depression, dysarthria, jaundice, skin rash, ataxia, constipation, headache, incontinence, changes in salivation, slurred speech, tremor, vertigo, urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances, stimulation have been reported; should these occur, discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts and liver function tests advisable during long-term therapy.

Dosage: Individualize for maximum beneficial effect. *Adults:* Anxiety disorders, symptoms of anxiety, 2 to 10 mg b.i.d. to q.i.d.; alcoholism, 10 mg t.i.d. or q.i.d. in first 24 hours, then 5 mg t.i.d. or q.i.d. as needed; adjunctively in skeletal muscle spasm, 2 to 10 mg t.i.d. or q.i.d.; adjunctively in convulsive disorders, 2 to 10 mg b.i.d. to q.i.d. *Geriatric or debilitated patients:* 2 to 2½ mg, 1 or 2 times daily initially, increasing as needed and tolerated. (See Precautions.) *Children:* 1 to 2½ mg t.i.d. or q.i.d. initially, increasing as needed and tolerated (not for use under 6 months).

Supplied: Valium® (diazepam/Roche) Tablets, 2 mg, 5 mg and 10 mg—bottles of 100 and 500; Tel-E-Dose® packages of 100, available in trays of 4 reverse-numbered boxes of 25, and in boxes containing 10 strips of 10; Prescription Paks of 50, available in trays of 10.

ROCHE®

Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Only Valium® (diazepam/Roche) has these two distinct effects

mind & muscle

-Antianxiety

-Skeletal muscle relaxant

2-mg, 5-mg, 10-mg
• scored tablets

Valium®
diazepam/Roche

Please see summary of product information on preceding page.

Indicated in anxiety disorders and as an adjunct in the relief of skeletal muscle spasm.

ROCHE®